亞盛醫藥-B(06855.HK)認購花旗系列金融產品
格隆匯9月10日丨亞盛醫藥-B(06855.HK)發佈公吿,公司於2021年3月至2021年6月期間認購花旗金融產品,共認購5次,金額分別為1991萬美元、500萬美元、3000萬港元、3000萬港元及4900萬元人民幣。
公司認為,花旗金融產品屬保本性質、為短期,而與花旗金融產品的預期回報有關的風險為低,且與作實際計劃用途前將該等閒置資金作為定期存款存入商業銀行比較,公司可從2021年配售事項的未動用所得款項淨額中獲得更高的回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.